Single-dose pharmacodynamics of minocycline against a mixed staphylococcal infection in an in vitro pharmacokinetics / pharmacodynamics model simulating human serum levels

Background: A mixed staphylococcal infection is a frequent opportunistic infection in immunocompromised patients and is often fatal, particularly in those with severe burns or other critical conditions. While S. aureus is typically the main culprit, S. epidermidis can also contribute significantly. Minocycline, a semisynthetic tetracycline antibiotic, can be effective on its own against multi-resistant staphylococcal infections. However, its exact effectiveness against different staphylococcal species is not fully known. Aim: We, herein, studied the efficacy of minocycline against two staphylococcal species (S. aureus ATCC 25923 and S. epidermidis ATCC-12228), either alone or together, by using a new in vitro pharmacokinetics / pharmacodynamics (PK/PD) system. Methodology: This PK/PD system simulates minocycline human plasma levels with a Cmax of 2 and 4 mg/L, and allowed us to monitor bacterial growth spectrophotometrically based on the relative optical density (ROD) at 600 nm. Results: These two staphylococcal isolates (S. aureus ATCC-25923 and S. epidermidis ATCC-12228) had minimum inhibitory concentrations (MICs) of 0.125 and 0.5 mg/L, respectively, which were tested in duplicate in an in vitro PK system with a fAUC0-24 and a half-life of 12 h. The area under the bacterial growth curve (AUGROD) was used as the PD parameter. The in vitro PK/PD relationship was then used in order to assess the efficacy of minocycline through the fAUC0-24-AUGROD relationship, which followed a sigmoid pattern (R2=0.874). Conclusion: The in vitro PK/PD modelling of minocycline’s activity showed that the standard dose of 4 mg/L can result in a drug exposure associated with maximal efficacy against each isolate, alone or together. However, a mixed staphylococcal infection with both isolates was associated with the best minocycline efficacy compared to S. aureus alone, although it was still non-significant.

Authors

Institutions

Publication Details

Journal
Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Published
2024-09-13
DOI
https://doi.org/10.61873/oslm1686
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Single-dose pharmacodynamics of minocycline against a mixed staphylococcal infection in an in vitro pharmacokinetics / pharmacodynamics model simulating human serum levels

Hussam Al‐Humadi, Rafal Al‐Saigh, Safa Jihad
Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Antibiotics Pharmacokinetics and Efficacy
article

Single-dose pharmacodynamics of minocycline against a mixed staphylococcal infection in an in vitro pharmacokinetics / pharmacodynamics model simulating human serum levels

Hussam Al‐Humadi, Rafal Al‐Saigh, Safa Jihad
article en

Abstract

Background: A mixed staphylococcal infection is a frequent opportunistic infection in immunocompromised patients and is often fatal, particularly in those with severe burns or other critical conditions. While S. aureus is typically the main culprit, S. epidermidis can also contribute significantly. Minocycline, a semisynthetic tetracycline antibiotic, can be effective on its own against multi-resistant staphylococcal infections. However, its exact effectiveness against different staphylococcal species is not fully known. Aim: We, herein, studied the efficacy of minocycline against two staphylococcal species (S. aureus ATCC 25923 and S. epidermidis ATCC-12228), either alone or together, by using a new in vitro pharmacokinetics / pharmacodynamics (PK/PD) system. Methodology: This PK/PD system simulates minocycline human plasma levels with a Cmax of 2 and 4 mg/L, and allowed us to monitor bacterial growth spectrophotometrically based on the relative optical density (ROD) at 600 nm. Results: These two staphylococcal isolates (S. aureus ATCC-25923 and S. epidermidis ATCC-12228) had minimum inhibitory concentrations (MICs) of 0.125 and 0.5 mg/L, respectively, which were tested in duplicate in an in vitro PK system with a fAUC0-24 and a half-life of 12 h. The area under the bacterial growth curve (AUGROD) was used as the PD parameter. The in vitro PK/PD relationship was then used in order to assess the efficacy of minocycline through the fAUC0-24-AUGROD relationship, which followed a sigmoid pattern (R2=0.874). Conclusion: The in vitro PK/PD modelling of minocycline’s activity showed that the standard dose of 4 mg/L can result in a drug exposure associated with maximal efficacy against each isolate, alone or together. However, a mixed staphylococcal infection with both isolates was associated with the best minocycline efficacy compared to S. aureus alone, although it was still non-significant.

Review of Clinical Pharmacology and Pharmacokinetics - International EditionVol. 38(3)
University of Babylon (IQ)
Good health and well-being
Openalex Percentile: Top 85%
Antibiotics Pharmacokinetics and Efficacy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.